The Reaumond Foundation's $500K Commitment to the EXTEND TRIAL

Written By Alyssa Cassata

We are pleased to share where our $500,000 commitment over the next five years to the University of Arizona Cancer Center is going—funding the innovative EXTEND TRIAL, a beacon of hope for pancreatic cancer patients.

Exciting Breakthrough in Pancreatic Cancer Research

Immunotherapy, though transformative for many cancers, has shown limited success in pancreatic cancer—until now. Recent trials have revealed that combining targeted therapies with traditional immunotherapy can significantly improve patient responses.

Key Findings:

  • Combination Therapy: University of Arizona Cancer Center's phase II trial, combining cabozantinib and atezolizumab, shows promise in treating metastatic pancreatic cancer.

  • Improved Outcomes: Patients receiving both radiation and chemotherapy had a median progression-free survival of 10.3 months compared to 2.5 months for those on chemotherapy alone.

  • Enhanced Immune Response: Notable activation of the immune system, with no moderate or severe toxicities observed.

This ongoing study, now enrolling 29 patients, offers a new ray of hope for those battling pancreatic cancer.

Your support helps us fund vital research like this, bringing us one step closer to better treatments and, ultimately, a cure.

Alyssa Cassata
Previous

Meet Betty, Our September Guest at Homes of Hope!

Next

Meet Lileesa, Our June Guest at Homes of Hope!